Skip to main content

Evolving Adjuvant Treatment Landscape for HR+/HER2- Early Breast Cancer

This first installment observes how the adjuvant treatment landscape has evolved for patients with HR+/HER2- early breast cancer, including discussion on the monarchE study.
Videos — December 19, 2023
Nadia Harbeck, MD, PhD
Director, Breast Cancer
Professor, Conservative Oncology
LMU University Hospital
Munich, Germany

Interview with the Innovators Presents:
Emerging Data in Early Breast Cancer from ESMO 2023

We are pleased to announce the release of our latest Interview with the Innovators video series. This 3-part video series features expert commentary from Dr Nadia Harbeck, MD, PhD, Ludwig-Maximilians-University of Munich. In this video series, Dr Harbeck recaps data on adjuvant treatment for patients with HR+/HER2- early breast cancer, details new data on prognostic factors in breast cancer, and discusses recent trials investigating neoadjuvant immunotherapy.

Related Items